COMMUNIQUÉS West-GlobeNewswire

Solon Eiendom ASA : Key information relating to the cash dividend proposed

28/02/2018 - 10:57

Oslo, 28 February 2018: Solon Eiendom ASA (OSE: SOLON) Dividend amount: NOK 1.15 per share Declared currency: NOK Last day including right: 23 May 2018 Ex-date: 24 May 2018 Record date: 25 May 2018 Payment date: 4 June [...]

Orion's statutory co-operation negotiations completed

28/02/2018 - 09:46

ORION CORPORATION PRESS RELEASE 28 FEBRUARY 2018 at 10.45 Orion's statutory co-operation negotiations completed Orion's co-operation negotiations regarding the laboratory operations of pharmaceutical production, quality [...]

Orphazyme recognizes Rare Disease Day 2018

28/02/2018 - 09:24

Orphazyme A/S Investor news No. 03/2018 Copenhagen, February 28, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases today announced its support [...]

Veritas Pharma Signs Memorandum of Understanding with BioCan Technologies

28/02/2018 - 09:05

VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of [...]

Biohit Group Financial Statement Release 2017

28/02/2018 - 08:30

Biohit Oyj Financial Statement Release, 28 February 2018 at 9:30 am local time (EET) SUMMARY January-December 2017 Net sales grew by 9.6 % compared to 2016 Net sales EUR 9.0 million (EUR 8.2 million) EBITDA EUR 7.9. [...]

Nexstim Plc: Invitation to the Annual General Meeting

28/02/2018 - 08:06

Company announcement, Helsinki, 28 February 2018 at 9:05 AM Nexstim Plc: Invitation to the Annual General Meeting Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a neuromodulation company developing and [...]

Solon Eiendom ASA : All time high results and dividend

28/02/2018 - 08:03

Solon Eiendom achieved all time high NGAAP results with revenue of NOK 1 128 million and EBITDA of NOK 207 million. IFRS operating revenues were also record high with NOK 883 million and an EBITDA of NOK 108 million in [...]

Xbrane Biopharma releases year-end report for 2017

28/02/2018 - 08:02

Press release 2018-02-28 Xbrane Biopharma AB's (publ.) ("Xbrane") year-end report for 2017 is now available on the Company's website, www.xbrane.com . Financial summary fourth quarter 2017 Revenue amounted to SEK 9,535 [...]

NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2017

28/02/2018 - 08:01

Company announcement, Helsinki, 28 February 2018 at 9:00 am NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a neuromodulation company developing and marketing [...]

Terveystalo Plc Financial statements release January 1-December 31, 2017

28/02/2018 - 08:01

Terveystalo Plc Stock Exchange Release 28 February 2018 at 9:00 EET Adjusted EBITDA for the full year 2017 increased by 26.7 per cent year-on-year to EUR 92.4 million (72.9) Highlights of the review period October- [...]

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - December 31, 2017

28/02/2018 - 08:01

Message from the CEO During the last year, IBT passed the most important milestones in the company's history. The company's pharmaceutical candidate, IBP-9414, for the prevention of necrotizing enterocolitis, has in a [...]

U.S. FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia (ALL)

28/02/2018 - 08:00

U.S. FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia (ALL) If approved, Cal-PEG could provide a new PEGylated asparaginase first-line treatment for [...]

On “Grindeks” results in 2017

28/02/2018 - 07:56

Today, on 28 February, the JSC “Grindeks” submitted the non-audited consolidated financial statements of 2017 to “Nasdaq Riga”. Non-audited financial results indicate that in 2017 turnover of the Group was 132.4 million [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

28/02/2018 - 07:06

REGULATED INFORMATION GHENT, Belgium, 28 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

ABLYNX ANNOUNCES CONVERSION OF BONDS

28/02/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 28 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that in relation to the €100,000,000, 3.25% Senior Unsecured Convertible Bonds due on 27 May 2020 ( [...]

MDxHealth contract SelectMDx with Roman Hospital

28/02/2018 - 07:01

NEWS RELEASE MDxHealth enters into commercial agreement for SelectMDx with Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata Hospital in Rome HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, February 28 [...]

COMMUNIQUE DE PRESSE MDxHealth Contrat Commercial

28/02/2018 - 07:01

COMMUNIQUÉ DE PRESSE MDxHealth conclut un contrat commercial avec Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata Hospital à Rome pour la vente du test SelectMDx HERSTAL, BELGIQUE et IRVINE, CA - 07 [...]

UPDATE- Adventist Health Selects Michelle Fuentes to Lead Adventist Health Sonora

28/02/2018 - 02:42

ROSEVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Adventist Health —a faith-based, nonprofit integrated health system serving more than 75 communities in California, Oregon and Hawaii—today announced the appointment [...]

AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain

28/02/2018 - 01:31

TOKYO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the treatment of the first patient with NF- [...]